Table 3 Intracellular cytokine production during acute exacerbation
Patient with JIA with acute exacerbation | JIA group (n=6) | HD group (n=6) | |
|---|---|---|---|
TNFα (percentage of CD4+CD45RA+) | 6.09 | 6.99±2.52 (6.37; 4.62 to 10.43) | 6.26±4.60 (4.47; 1.82 to 12.9) |
IFNα (percentage of CD4+CD45RA+) | 19.63* | 2.77±1.24 (2.60; 1.15 to 4.39) | 4.04±2.21 (3.52; 1.39 to 7.49) |
IL-2 (percentage of CD4+CD45RA+) | 53.74 | 37.63±31.49 (28.65; 5.53 to 81.25) | 14.68±9.79 (14.54; 3.12 to 28.56) |
TNFα (percentage of CD4+CD45RO+) | 41.99* | 21.11±9.17 (21.18; 7.74 to 34.36) | 18.19±8.79 (15.38; 11.31 to 34.69) |
IFNα (percentage of CD4+CD45RO+) | 41.23* | 10.05±4.09 (10.12; 4.52 to 14.46) | 13.30±6.07 (12.08; 8.21 to 24.21) |
IL-2 (percentage of CD4+CD45RO+) | 79.77 | 50.09±30.69 (41.09; 15.65 to 90.03) | 31.01±22.65 (24.37; 8.56 to 60.41) |
TNFα (percentage of CD8+CD45RA+) | 8.19 | 7.05±3.64 (6.40; 2.70 to 21.30) | 5.39±4.04 (4.35; 1.44 to 11.80) |
IFNγ (percentage of CD8+CD45RA+) | 18.21 | 11.27±8.12 (8.19; 4.49 to 24.05) | 8.68±5.13 (6.86; 4.61 to 18.20) |
IL-2 (percentage of CD8+CD45RA+) | 54.61* | 25.73±26.00 (16.35; 6.63 to 17.52) | 12.49±9.45 (8.44; 3.99 to 25.89) |
TNFα (percentage of CD8+CD45RO+) | 68.22* | 24.04±10.02 (27.43; 11.44 to 33.10) | 22.98±9.35 (22.6; 12.27 to 35.64) |
IFNγ (percentage of CD8+CD45RO+) | 83.67* | 28.26±19.57 (27.43; 2.63 to 50.26) | 34.77±17.44 (33.33; 9.14 to 61.50) |
IL-2 (percentage of CD8+CD45RO+) | 73.48* | 34.82±15.52 (31.53; 17.52 to 58.08) | 23.84±22.63 (12.86; 4.58 to 60.27) |